Efficacy and safety of long acting injectable atypical antipsychotics: a review.
Schizophrenia is a chronic, severe and recurrent brain disorder that requires continuous, long-term treatment with antipsychotic medication to minimize relapse and provide clinical benefit to patients. For patients with schizophrenia, non-adherence to medication is a major risk factor for relapse and re-hospitalization. Long-acting injectable formulations of second-generation antipsychotics (SGAs-LAIs) provide constant medication delivery and the potential for improved adherence. Currently, three drugs are available for the treatment of schizophrenia, risperidone longacting injectable, olanzapine pamoate and paliperidone palmitate. Several studies have also demonstrated efficacy and safety of such drugs in patients with acute schizophrenia. In the present paper the literature on LAI atypical antipsychotics will be reviewed and practical advice will be given concerning the use of these drugs in the clinical practice.
NHS, Department of Mental Health, Psychiatric Service of Diagnosis and Treatment, Hospital, G. Mazzini, Asl 4, Teramo, Italy. dodebera@aliceposta.it
Domenico
D
De Berardis
Stefano
S
Marini
Alessandro
A
Carano
Antonella Padovan
AP
Lang
Marilde
M
Cavuto
Monica
M
Piersanti
Michele
M
Fornaro
Giampaolo
G
Perna
Alessandro
A
Valchera
Monica
M
Mazza
Felice
F
Iasevoli
Giovanni
G
Martinotti
Massimo
M
Di Giannantonio
D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D003692:Delayed-Action Preparations; D016503:Drug Delivery Systems; D006801:Humans; D007267:Injections; D007555:Isoxazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D055118:Medication Adherence; D000077152:Olanzapine; D000068882:Paliperidone Palmitate; D010168:Palmitates / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D018967:Risperidone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy* / Q000503:physiopathology
D014150:Antipsychotic Agents; D003692:Delayed-Action Preparations; D007555:Isoxazoles; D010168:Palmitates; D001569:Benzodiazepines; D018967:Risperidone; D000077152:Olanzapine; D000068882:Paliperidone Palmitate